Nuvectis Pharma, Inc.

NASDAQ:NVCT

Biotechnology

Healthcare
$19.84 +3.06%

+$0.39 today

Market cap
$682.28M
Beta
-0.07
P/E (TTM)
-11.2
EPS (TTM)
-$1.16
52W Low $5.55High $13.51

Volume 0.16M

Average 0.08M

Returns on capital

Nuvectis Pharma, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-143.6%

avg -73.1%

ROIC

-149.8%

avg -146.9%

ROA

-83.4%

avg -98.1%

Analysis

ROA is currently the strongest return metric at -83.4% versus its period average of -98.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Ron Bentsur

Co-Founder, Chairman, Chief Executive Officer & PresidentUSD 1.19M603.69M13.91%

Shay Shemesh

Co-Founder, Executive Vice President, Chief Development & Operations OfficerUSD 749.24K421.79M6.76%

Enrique Poradosu

Co-Founder, Executive Vice President, Chief Scientific & Business OfficerUSD 749.24K591.81M6.81%

Michael Carson

Vice President of Finance—50——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 30, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$1.17M

Sells

0

$0.00

Net Transaction Value

+$1.17M

Net buying

Most Active

Mosseri Marlio Charles

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 30, 26

Mosseri Marlio Charles

Indirect

Buy$916K
Jun 30, 26

BENTSUR RON

Direct

Buy$250K

Summary

Insiders reported 2 buys worth $1.17M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.17M. Mosseri Marlio Charles was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Nuvectis Pharma, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NVCT's management, answered from reported figures.

Who manages NVCT?

Nuvectis Pharma, Inc. (NVCT) lists 4 active executives. The top listed executive is Ron Bentsur, Co-Founder, Chairman, Chief Executive Officer & President.

Are NVCT insiders buying or selling?

Recent insider activity shows net buying of $11.21M.